Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Undertreatment of Newly-Diagnosed MM Evaluated

Clin Lymphoma Myeloma Leuk; ePub 2018 Feb 3; Fakhri, et al

Certain age, health status, race, and socioeconomic factors appear to be linked with receiving no treatment for multiple myeloma (MM), according to a study involving nearly 4,200 individuals. Participants were from the 2007-2011 SEER-Medicare database and had plasma cell myeloma. Investigators looked at factors linked with receiving no treatment for MM. Among the results:

  • 373 had no claims showing MM treatment nor ICD-9 codes for MM-defining clinical features.
  • Of ~3,800 patients with active MM, 4 in every 10 had no claims for systemic treatment.
  • Patients who were older, had poor performance indicators, and had comorbidities were more likely to receive no systemic treatment.
  • The same was true for blacks, those with lower socioeconomic status, and patients receiving Medicaid.


Fakhri B, Fiala M, Tuchman S, Wildes T. Undertreatment of older patients with newly diagnosed multiple myeloma in the era of novel therapies. [Published online ahead of print February 3, 2018]. Clin Lymphoma Myeloma Leuk. doi: 10.1016/j.clml.2018.01.005.

Must Reads in Myelodysplastic Syndrome

Gene sequencing bone marrow in myelodysplastic syndrome, Duncavage EJ et al. N Engl J Med 2018;379:1028-41.

JAK1/2 inhibitors tied to increased B-cell lymphoma risk, Porpaczy E et al. Blood. 2018 Jun 14. doi: 10.1182/blood-2017-10-810739.

Romiplostim safety confirmed in thrombocytopenic patients with low-risk myelodysplastic syndromes, Kantarjian H et al. The Lancet Haematology March 2018, Pages e117-e126

Simplifying the URD Selection Process for HCT, Biol Blood Marrow Transplant.; ePub 2018 Feb 14; Shaw, Logan, et al

Genetic Risk Model for MDS Shown to Be Feasible, Am J Hematol; ePub 2018 Feb 24; Gangat, et al